Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:~  1. Smoking history of at least 10 pack-years~ 2. Post-bronchodilator FEV1 \<80% and ≥30% of the predicted normal value~ 3. Post-bronchodilator FEV1/FVC (forced vital capacity) \<70%~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization for in the 6 weeks prior to screening~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 75 µg (Type: EXPERIMENTAL): Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).